These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus. Triplitt C; Wright A; Chiquette E Pharmacotherapy; 2006 Mar; 26(3):360-74. PubMed ID: 16503716 [TBL] [Abstract][Full Text] [Related]
5. New insights into glucose regulation. Kruger DF; Martin CL; Sadler CE Diabetes Educ; 2006; 32(2):221-8. PubMed ID: 16554425 [TBL] [Abstract][Full Text] [Related]
6. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus. Freeman JS Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298 [TBL] [Abstract][Full Text] [Related]
7. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091 [TBL] [Abstract][Full Text] [Related]
8. Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. Ranganath LR J Clin Pathol; 2008 Apr; 61(4):401-9. PubMed ID: 18375745 [TBL] [Abstract][Full Text] [Related]
9. [Diabetes mellitus and osteoporosis. Incretin as a coordinator of glucose and bone metabolism]. Yamada Y Clin Calcium; 2012 Sep; 22(9):1353-8. PubMed ID: 22932289 [TBL] [Abstract][Full Text] [Related]
10. Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility. Knop FK; Holst JJ; Vilsbøll T IDrugs; 2008 Jul; 11(7):497-501. PubMed ID: 18600596 [TBL] [Abstract][Full Text] [Related]
11. GLP-1: broadening the incretin concept to involve gut motility. Hellström PM Regul Pept; 2009 Aug; 156(1-3):9-12. PubMed ID: 19362109 [TBL] [Abstract][Full Text] [Related]
12. Beyond glycemic control: the effects of incretin hormones in type 2 diabetes. Martin CL Diabetes Educ; 2008; 34 Suppl 3():66S-72S. PubMed ID: 18525067 [TBL] [Abstract][Full Text] [Related]
13. [Incretin strategy in the treatment of type 2 diabetes mellitus--DPPIV]. Perusicová J Vnitr Lek; 2007 Sep; 53(9):1005-9. PubMed ID: 18019673 [TBL] [Abstract][Full Text] [Related]
14. [Incretin-mimetic drugs, an insulin alternative in type 2 diabetes]. Fabreegas B Soins; 2008 Jun; (726):34-7. PubMed ID: 18697336 [No Abstract] [Full Text] [Related]
15. Glucagon-like peptide-1: glucose homeostasis and beyond. Cho YM; Fujita Y; Kieffer TJ Annu Rev Physiol; 2014; 76():535-59. PubMed ID: 24245943 [TBL] [Abstract][Full Text] [Related]
16. Comment on: Villareal et al. (2009) TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes;59:479-485. Knop FK Diabetes; 2010 Jun; 59(6):e4; author reply e5-6. PubMed ID: 20508220 [No Abstract] [Full Text] [Related]
17. The entero-insular axis in type 2 diabetes--incretins as therapeutic agents. Creutzfeldt W Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S288-303. PubMed ID: 11460578 [TBL] [Abstract][Full Text] [Related]
18. Incretins: the novel therapy of type 2 diabetes. Thongtang N; Sriwijitkamol A J Med Assoc Thai; 2008 Jun; 91(6):943-54. PubMed ID: 18697398 [TBL] [Abstract][Full Text] [Related]
19. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Theodorakis MJ; Carlson O; Michopoulos S; Doyle ME; Juhaszova M; Petraki K; Egan JM Am J Physiol Endocrinol Metab; 2006 Mar; 290(3):E550-9. PubMed ID: 16219666 [TBL] [Abstract][Full Text] [Related]
20. The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance. Knop FK; Vilsbøll T; Højberg PV; Larsen S; Madsbad S; Holst JJ; Krarup T Regul Pept; 2007 Dec; 144(1-3):123-30. PubMed ID: 17692937 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]